• Resize Text
    • Small Text
    • Medium Text
    • Large Text
    • Connect

Rosemont Invests in New Innovation Centre to Increase Company Growth

Rosemont Pharmaceuticals - Rosemont's new innovation centre - people working in a lab

The building officially opened on 6th May 2022, less than 12 months after construction started, and enables Rosemont to support the further development of its market leading liquid medicine range, working to help more people across the globe.

The state of the art laboratories and offices in the Innovation Centre allows for the expansion of product manufacture, enabling scientists to work on more projects and bring products to market at a quicker pace.

Rosemont’s aim is to increase the company’s liquid medicine output to serve even more international markets and enhance company growth. It also provides the opportunity for the development team to work on more complex products, new formats and increase the product offering to both healthcare professionals and their patients.

With the centre located on the same site as the production facility, better collaboration when working between departments will be made easier, boosting productivity. Furthermore, by bringing the research and development team onto the main Rosemont site, ease of communication within the business will be improved. This will bring many benefits to Rosemont’s working practices and capabilities.

The investment and expansion of the site also benefits the local area of Leeds. The Innovation Centre alone is predicted to create 9 new job opportunities in the next year, while Rosemont’s other business areas aim to employ a further 11 members of staff.

With over 50 years of expertise in the development, manufacture and distribution of oral liquid medicines, Rosemont is committed to supporting patients with swallowing difficulties. This important investment will enhance the capabilities for international distribution, support the additional regulatory requirements and firmly place Rosemont as innovators in the world of pharmaceutical research and development.

Ed Cahill, Chief Scientific Officer, Rosemont Pharmaceuticals says: “The Innovation Centre is the foundation for our future growth plans, enabling us to meet the new demands of the business. By bringing all Rosemont’s scientific functions under one roof, the development process is at the centre of everything we do, which enables us to innovate and bring to market more products at a rapid pace”

DTM490 DOP February 2023